All In Biotech

Free tool

FAERS Monitor: Adbry

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761180 or its brand name (Adbry, Tralokinumab). Reports on generic versions are filed under their own applications.

Reports

6,706

Serious

923

14% of reports

Hospitalization

340

Death reported

90

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dermatitis atopic900
  • drug ineffective856
  • pruritus735
  • rash496
  • eczema465
  • injection site pain432
  • dry skin287
  • injection site erythema239
  • erythema225
  • product use in unapproved indication223
  • injection site pruritus208
  • injection site swelling198
  • eye pruritus182
  • ocular hyperaemia175
  • skin exfoliation167

Reports by year received

View as table
YearReports
20202
20211
2022549
20231,020
20241,641
20251,894
20261,599

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,453 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dermatitis atopicSignal90054.451.246,475
eczemaSignal46528.125.712,054
eye pruritusSignal18217.114.82,728
ocular hyperaemiaSignal17511.610.01,683
injection site pruritusSignal2089.88.51,628
injection site swellingSignal1988.17.11,231
dry skinSignal2876.86.01,408
skin exfoliationSignal1676.25.4728
injection site erythemaSignal2396.15.31,007
pruritusSignal7356.05.63,114
injection site painSignal4324.44.01,156
rashSignal4963.63.3934
erythemaSignal2253.43.0389
product use in unapproved indicationSignal2232.82.5264
drug ineffectiveSignal8562.01.9481

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.